Navigation Links
N30 Pharma Announces Financing and Addition to Board
Date:5/11/2010

BOULDER, Colo., May 11 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery and development of a new class of proprietary therapeutics that conserve endogenous, bioactive nitric oxide, announced today that it has completed a $10 million financing and expanded its Board of Directors.

Joining the Company's Board of Directors will be Dr. Howard Furst of Deerfield Management.

"I am pleased with this successful financing. It will provide resources to move our first drug, N6022 into human testing, as well as support the development of other novel new drugs from our discovery and development platform. In addition, Dr. Furst brings a wealth of healthcare investment and medical expertise to our Board," commented Charles Scoggin MD, CEO of N30.

About N30 Pharma N30 Pharma is a clinical-stage company developing s-nitrosothiol (SNO)-based therapies for major unmet needs in respiratory, cardiovascular, and inflammatory diseases. N30 drugs target s-nitrosoglutathione reductase (GSNOR), the only druggable enzyme that consumes s-nitrosoglutathione (GSNO), a central regulator of the endogenous nitric oxide pool. GSNO, and other SNO's are important modulators of inflammation as well as airway and vascular smooth muscle. N30 is a privately held company headquartered in Boulder, Colorado.


'/>"/>
SOURCE N30 Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
5. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... Researchers ... from small lab samples to full-size tissues, bones, even whole organs to implant ... system that delivers blood deep into the developing tissue. , Current bioengineering ...
(Date:3/22/2017)... , March 22, 2017 Good Start Genetics, ... has eclipsed the 130 million covered lives mark through ... of Texas . With newly signed ... continues to enjoy strong payor acceptance based on the ... programs and genetic counseling, its industry-leading customer care and ...
(Date:3/22/2017)... , March 22, 2017 The ... states a research report by Transparency Market Research (TMR). ... Amgen Inc., and AbbVie Inc., accounted for a share ... prominent players in this market are focusing aggressively on ... portfolio, which is likely to lead to market consolidation ...
(Date:3/22/2017)... , March 22, 2017   Boston Biomedical ... cancer therapeutics designed to target cancer stemness pathways, today ... S. Andrews as Chief Executive Officer, effective April ... Chiang J. Li , M.D., FACP, who has ... years ago. Under his leadership, Boston Biomedical has grown ...
Breaking Biology Technology:
(Date:3/2/2017)... NEW YORK , March 2, 2017 Summary ... to better understand Perrigo and its partnering interests and activities ... ... The Partnering Deals and Alliance since 2010 report provides an ... world,s leading life sciences companies. On demand company ...
(Date:3/2/2017)... 2017 Who risk to be deprived of ... full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
(Date:3/1/2017)... , March 1, 2017  Aware, Inc. (NASDAQ: ... announced that Richard P. Moberg has resigned, ... co-President and Chief Financial Officer and Treasurer of Aware ... to serve as a member of the Board of ... , Aware,s co-Chief Executive Officer and co-President, General Counsel ...
Breaking Biology News(10 mins):